ClinicalTrials.gg
TerminatedNCT03287271Updated Jul 31, 2026Results posted

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

A Phase 1/2 interventional study of VS-6063 and Paclitaxel in Ovarian Cancer, sponsored by Michael McHale. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Michael McHale · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Due to loss of funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 276 open to participants now, 452 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Enrollment
1,344th of 1,499
8 · median 47
Started
2018
with 75 others
Phase 1/2
222 of 1,780
47 open now
Registered
1,064th of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 1,344th largest by enrollment of the 1,499 interventional ones that give a count, is one of 76 that started in 2018, is one of 222 in phase 1/2, and was the 1,064th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

276 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

271 more — sign in →

All 276 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer.

Read the detailed description

The purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer. The study will evaluate whether this regimen is safe. The study will also evaluate whether the regimen can reduce the amount of cancerous cells in your body. If you agree, you will be treated with VS-6063 by mouth, as well as carboplatin and paclitaxel infusions. Carboplatin and paclitaxel are approved by the FDA for the treatment of ovarian cancer. VS-6063 is considered experimental because it is not approved by the FDA for the treatment of cancer.

03

Conditions studied

  • Ovarian Cancer

Keywords

  • ovarian cancer
  • cancer
  • ovary
  • carboplatin
  • paclitaxel
  • VS-6063
  • primary peritoneal carcinoma
  • fallopian tube
  • defactinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma, diagnosed within 6 months of completing their most recent platinum-containing chemotherapy.
  • Patients with the following histologic cell types are eligible: Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma not otherwise specified (N.O.S.)
  • Must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. This initial treatment may have included intraperitoneal therapy, high-dose therapy, consolidation, noncytotoxic agents or extended therapy administered after surgical or non-surgical assessment.
  • Must have NOT received more than two total prior lines of cytotoxic chemotherapy for management of recurrent or persistent disease, including retreatment with initial chemotherapy regimens.
  • May have received one additional non-cytotoxic regimen for management of recurrent or persistent disease according to the following definition: Non-cytotoxic (biologic or cytostatic) agents include (but are not limited to) hormones, monoclonal antibodies, cytokines, and small molecule inhibitors of signal transduction.
  • Women of must have a negative serum pregnancy test prior to study entry and be practicing an effective form of .

Must have adequate:

  • Bone marrow function
  • Renal function
  • Hepatic function
  • Neurologic function
  • Recovered from effects of recent surgery, radiotherapy, or chemotherapy. All persistent toxicities from prior chemotherapy must be less than or equal to Grade 1.
  • Free of active infection requiring antibiotics (with the exception of uncomplicated UTI).
  • Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration.

Exclusion criteria

Exclusion Criteria:

  • Platinum- ovarian, fallopian tube, or primary peritoneal carcinoma.
  • Known second primary or prior diagnosed within 5 years of study start date (other than previously treated non-melanoma skin cancer).
  • Current treatment with chemotherapy or radiation therapy. Any prior therapy directed at the malignant tumor, including biologic and immunologic agents, must be discontinued at least three weeks prior to registration.
  • History of treatment with known kinase inhibiting agents.
  • History of gastrointestinal fistula, hemorrhage, perforation or peptic ulcer disease.
  • Patients who are pregnant or breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel

    Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel

    Drug: VS-6063 · Drug: Paclitaxel · Drug: Carboplatin

  • Experimental
    Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel

    Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel

    Drug: VS-6063 · Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • Phase 1: * First 3 patient cohort: VS-6063 200 mg PO twice daily * IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily, Phase 2: VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity.

    Also known as: defactinib

  • Phase 1: * First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle. * IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle. Phase 2: Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity.

    Also known as: Taxol

  • Phase 1: * First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle. * IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle. Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity.

    Also known as: Paraplatin

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity

    Safety and tolerability of VS-6063 plus paclitaxel and carboplatin chemotherapy (Measured Via Adverse Events)

    Time frame: 28 days

  2. Objective Response Rate (ORR)

    Time frame: 4 years

Secondary outcomes

  1. To Assess the Toxicity and Adverse Event Profile of VS-6063 Plus Paclitaxel and Carboplatin Chemotherapy (Measured Via Adverse Events)

    Time frame: 4 years

  2. To Describe Health-related Quality-of-life (QoL) Outcomes of Patients Receiving VS-6063 Plus Paclitaxel and Carboplatin Chemotherapy. (Measured Via Questionnaire)

    Time frame: 4 years

  3. Progression Free Survival (PFS)

    Time frame: 4 years

  4. Overall Survival (OS)

    Time frame: 4 years

07

Results

Posted Jul 31, 2026

Participant flow

Participant flow — Overall Study
MilestoneDefactinib (VS-6063) (200 mg) + Carboplatin/PaclitaxelDefactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel
Started62
Completed42
Not completed20
Withdrew: Screen failure20

Outcome measures

PrimaryDose-Limiting Toxicity

Safety and tolerability of VS-6063 plus paclitaxel and carboplatin chemotherapy (Measured Via Adverse Events)

Time frame:
28 days
Reported as:
Count of participants · Participants
Dose-Limiting Toxicity
ParticipantsDefactinib (VS-6063) (200 mg) + Carboplatin/PaclitaxelDefactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel
Dose-Limiting Toxicity11
PrimaryObjective Response Rate (ORR)
Time frame:
4 years
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsDefactinib (VS-6063) + Carboplatin/Paclitaxel
Objective Response Rate (ORR)0
SecondaryTo Assess the Toxicity and Adverse Event Profile of VS-6063 Plus Paclitaxel and Carboplatin Chemotherapy (Measured Via Adverse Events)
Time frame:
4 years
Reported as:
Count of participants · Participants
To Assess the Toxicity and Adverse Event Profile of VS-6063 Plus Paclitaxel and Carboplatin Chemotherapy (Measured Via Adverse Events)
ParticipantsDefactinib (VS-6063) +Carboplatin/Paclitaxel
To Assess the Toxicity and Adverse Event Profile of VS-6063 Plus Paclitaxel and Carboplatin Chemotherapy (Measured Via Adverse Events)0
SecondaryTo Describe Health-related Quality-of-life (QoL) Outcomes of Patients Receiving VS-6063 Plus Paclitaxel and Carboplatin Chemotherapy. (Measured Via Questionnaire)
Time frame:
4 years
Reported as:
Count of participants · Participants
To Describe Health-related Quality-of-life (QoL) Outcomes of Patients Receiving VS-6063 Plus Paclitaxel and Carboplatin Chemotherapy. (Measured Via Questionnaire)
ParticipantsDefactinib (VS-6063) +Carboplatin/Paclitaxel
To Describe Health-related Quality-of-life (QoL) Outcomes of Patients Receiving VS-6063 Plus Paclitaxel and Carboplatin Chemotherapy. (Measured Via Questionnaire)0
SecondaryProgression Free Survival (PFS)
Time frame:
4 years
Reported as:
Count of participants · Participants
Progression Free Survival (PFS)
ParticipantsDefactinib (VS-6063) +Carboplatin/Paclitaxel
Progression Free Survival (PFS)0
SecondaryOverall Survival (OS)
Time frame:
4 years
Reported as:
Count of participants · Participants
Overall Survival (OS)
ParticipantsDefactinib (VS-6063) +Carboplatin/Paclitaxel
Overall Survival (OS)0

Adverse events

Collected over 22 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel0/4 (0%)2/4 (50%)3/4 (75%)
Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel0/2 (0%)1/2 (50%)1/2 (50%)
Most frequent serious events
Most frequent serious events
EventDefactinib (VS-6063) (200 mg) + Carboplatin/PaclitaxelDefactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel
Colonic ObstructionGastrointestinal disorders1/41/2
Elevated White Blood Cell CountBlood and lymphatic system disorders1/40/2
Most frequent other events
Most frequent other events
EventDefactinib (VS-6063) (200 mg) + Carboplatin/PaclitaxelDefactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel
Neutrophil count decreasedBlood and lymphatic system disorders3/40/2
AnemiaBlood and lymphatic system disorders1/41/2
FatigueGeneral disorders1/40/2
White blood cell decreasedBlood and lymphatic system disorders1/40/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)Defactinib (VS-6063) (200 mg) + Carboplatin/PaclitaxelDefactinib (VS-6063) (400 mg) + Carboplatin/PaclitaxelTotal
Median58.5 (41 to 66)60.5 (56 to 65)60 (41 to 66)
Sex: Female, Male
Sex: Female, Male(Participants)Defactinib (VS-6063) (200 mg) + Carboplatin/PaclitaxelDefactinib (VS-6063) (400 mg) + Carboplatin/PaclitaxelTotal
Female426
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Defactinib (VS-6063) (200 mg) + Carboplatin/PaclitaxelDefactinib (VS-6063) (400 mg) + Carboplatin/PaclitaxelTotal
Hispanic or Latino213
Not Hispanic or Latino213
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Defactinib (VS-6063) (200 mg) + Carboplatin/PaclitaxelDefactinib (VS-6063) (400 mg) + Carboplatin/PaclitaxelTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White325
More than one race101
Unknown or Not Reported000
recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal
recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal(Participants)Defactinib (VS-6063) (200 mg) + Carboplatin/PaclitaxelDefactinib (VS-6063) (400 mg) + Carboplatin/PaclitaxelTotal
Count of participants426
08

Study locations

1 site
  • University of California San Diego
    San Diego, California 92023, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jul 2023, 65 months.

Results were first posted in Jul 2026, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2017
First posted
Sep 19, 2017
StartActual
Feb 6, 2018
Primary completionActual
Jul 30, 2023
CompletionActual
Mar 12, 2025
Results first posted
Jul 31, 2026
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03287271
Lead sponsor
Michael McHale
Collaborators
Verastem, Inc., Nine Girls Ask
Responsible party
Michael McHale (Clinical Professor, University of California, San Diego) — Sponsor-investigator
First posted
Sep 19, 2017
Start date
Feb 6, 2018
Primary completion
Jul 30, 2023
Completion
Mar 12, 2025
Results posted
Jul 31, 2026
Last update
Jul 31, 2026

Study contacts

Michael McHale
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion